$ 80.95
Key Takeaways
Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of DXCM is 100 and suggests 23% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
